Comparison of PLA-Based Micelles and Microspheres as Carriers of Epothilone B and Rapamycin. The Effect of Delivery System and Polymer Composition on Drug Release and Cytotoxicity against MDA-MB-231 Breast Cancer Cells.
MDA-MB-231 cells
PLA
PLA–PEG
breast cancer
controlled drug delivery system
cytotoxicity
epothilone B
micelles
microspheres
rapamycin
Journal
Pharmaceutics
ISSN: 1999-4923
Titre abrégé: Pharmaceutics
Pays: Switzerland
ID NLM: 101534003
Informations de publication
Date de publication:
05 Nov 2021
05 Nov 2021
Historique:
received:
28
09
2021
revised:
27
10
2021
accepted:
03
11
2021
entrez:
27
11
2021
pubmed:
28
11
2021
medline:
28
11
2021
Statut:
epublish
Résumé
Co-delivery of epothilone B (EpoB) and rapamycin (Rap) increases cytotoxicity against various kinds of cancers. However, the current challenge is to develop a drug delivery system (DDS) for the simultaneous delivery and release of these two drugs. Additionally, it is important to understand the release mechanism, as well as the factors that affect drug release, in order to tailor this process. The aim of this study was to analyze PLA-PEG micelles along with several types of microspheres obtained from PLA or a mixture of PLA and PLA-PEG as carriers of EpoB and Rap for their drug release properties and cytotoxicity against breast cancer cells. The study showed that the release process of EpoB and Rap from a PLA-based injectable delivery systems depends on the type of DDS, morphology, and polymeric composition (PLA to PLA-PEG ratio). These factors also affect the biological activity of the DDS, because the cytotoxic effect of the drugs against MDA-MB-231 cells depends on the release rate. The release process from all kinds of DDS was well-characterized by the Peppas-Sahlin model and was mainly controlled by Fickian diffusion. The conducted analysis allowed also for the selection of PLA 50/PLA-PEG 50 microspheres and PLA-PEG micelles as a promising co-delivery system of EpoB and Rap.
Identifiants
pubmed: 34834296
pii: pharmaceutics13111881
doi: 10.3390/pharmaceutics13111881
pmc: PMC8624627
pii:
doi:
Types de publication
Journal Article
Langues
eng
Subventions
Organisme : Medical University of Silesia
ID : PCN-1-166/K/0/F
Références
Adv Drug Deliv Rev. 2016 Dec 15;107:163-175
pubmed: 27426411
Drugs. 2012 Mar 26;72(5):705-13
pubmed: 22439671
Nat Rev Mater. 2016 Dec;1(12):
pubmed: 29657852
J Control Release. 2017 Dec 28;268:176-183
pubmed: 29056443
Bratisl Lek Listy. 2020;121(4):308-315
pubmed: 32356448
Breast Cancer Res. 2002;4(3):95-9
pubmed: 12052251
Int J Nanomedicine. 2010 Nov 26;5:1057-65
pubmed: 21170353
Mater Sci Eng C Mater Biol Appl. 2016 Sep 1;66:51-65
pubmed: 27207038
Mater Sci Eng C Mater Biol Appl. 2018 Jul 1;88:32-45
pubmed: 29636136
J Biol Chem. 2003 Nov 7;278(45):44886-93
pubmed: 12933799
Front Oncol. 2020 Nov 12;10:563779
pubmed: 33282730
Int J Pharm. 2011 Aug 30;415(1-2):34-52
pubmed: 21640806
J Biomed Mater Res A. 2021 Sep;109(9):1693-1700
pubmed: 33719211
Int J Pharm. 2017 Feb 25;518(1-2):307-311
pubmed: 28062368
Biomaterials. 2012 Jan;33(2):679-91
pubmed: 22019123
Drug Deliv. 2016 Sep;23(7):2262-2271
pubmed: 25317753
AAPS J. 2010 Sep;12(3):263-71
pubmed: 20373062
Cancers (Basel). 2014 Oct 24;6(4):2187-223
pubmed: 25347122
Eur J Pharm Sci. 2001 May;13(2):123-33
pubmed: 11297896
Oncol Lett. 2018 Apr;15(4):5781-5786
pubmed: 29545903
Eur J Pharm Biopharm. 2009 Jan;71(1):64-70
pubmed: 18703139
Front Pharmacol. 2018 Mar 08;9:202
pubmed: 29662450
Pharmaceutics. 2020 Jun 02;12(6):
pubmed: 32498326
Sci Rep. 2020 Aug 25;10(1):14188
pubmed: 32843673
Int J Pharm. 2016 Aug 20;510(1):365-74
pubmed: 27346726
Onco Targets Ther. 2015 Jan 16;8:177-93
pubmed: 25653541
Int J Pharm. 2019 Feb 25;557:43-52
pubmed: 30576789
Pharmaceutics. 2018 Nov 16;10(4):
pubmed: 30453503
Mater Sci Eng C Mater Biol Appl. 2017 Feb 1;71:268-278
pubmed: 27987708
J Control Release. 2012 Feb 28;158(1):53-62
pubmed: 22037107
Pharmaceutics. 2020 Dec 07;12(12):
pubmed: 33297493